28.3 C
Vientiane
Friday, June 20, 2025
spot_img
Home Blog Page 47

U.S. Marshal to Hold a Public Auction of 1,951,443 shares of Common Stock of Future FinTech Pursuant to the NY Court in Favor of FT Global Capital

MIAMI BEACH, Fla., June 2, 2025 /PRNewswire/ — FT Global Capital, Inc. (“FT Global”), a Miami Beach-based registered broker-dealer and investment banking firm, announced today the most recent development in its effort to enforce its judgment against Future FinTech Group Inc. (Nasdaq: FTFT) (“Future FinTech”). Following the U.S. District Court’s Order granting FT Global’s Motions for Turnover of Unissued Stock and Bank Funds (the “Court Order”), the U.S. Marshal or its representatives will hold a public auction in front of Room 850 of the Courthouse for the United States District Court for the Southern District of New York, 500 Pearl Street, New York, New York 10007 on June 12, 2025, at 12:00 noon, of 1,951,443 shares of FTFT common stock (the “Securities”).

At this auction, the Securities will be sold “as is,” without any warranty, and subject to any and all encumbrances, if any. The Securities have not been registered under the U.S. Securities Act of 1933, as amended, and will be issued with customary restrictive legends. The Securities will be offered solely to “accredited investors,” as that term is defined in the federal securities regulations. Any purchaser of the Securities must be prepared to comply with all reporting obligations under the federal securities law. Information about FTFT is available on the Securities and Exchange Commission EDGAR website. The auction of the Securities is not a public offering.

On April 16, 2024, the U.S. District Court for the Northern District of Georgia entered an Amended Judgment in favor of FT Global against Future FinTech in the approximate amount of $10.8 million. FT Global has entered the Amended Judgment in the Southern District of New York, among other courts. To date, a significant portion of the Amended Judgment remains unpaid. FT Global intends to work with the U.S. Marshal in connection with the Court Order to pay down the Amended Judgment.

FT Global will continue with its enforcement effort domestically and in foreign jurisdictions, as may be appropriate, against Future FinTech and its officers and directors.

About FT Global Capital, Inc.

FT Global Capital, Inc. is an investment banking firm and a FINRA member firm based in Miami Beach, FL and New York, NY.

Olshan Frome Wolosky LLP, a New York law firm, serves as FT Global’s litigation counsel. FT Global has also retained local counsel in various jurisdictions to prosecute its enforcement efforts, noted above.

About Future FinTech

Future FinTech Group Inc.’s filings made with the U.S. Securities and Exchange Commission are at https://www.sec.gov/edgar/search/#/ciks=0001066923&entityName=Future%2520FinTech%2520Group%2520Inc.%2520(FTFT)%2520(CIK%25200001066923).

Maxim’s de Paris expands to the US market with cutting-edge ‘Seine X’ home coffee machine

Bringing the Parisian café to American homes

PARIS, June 2, 2025 /PRNewswire/ — Maxim’s de Paris has announced its entry into the competitive US home coffee market with the launch of ‘Seine X’ – the world’s first intelligent semi-automatic three-in-one variable pressure espresso machine, a category-defining innovation in the premium home coffee segment. The cutting-edge machine blends intelligent technology, personalized features, and classic French design to instil le joie de vivre from the comfort of the home.

Maxim's La Seine X espresso machine
Maxim’s La Seine X espresso machine

Inspired by the iconic French car from the 1950s, the ‘Simca 9’, it took four years of R&D to create Seine X. Industry insiders have called the coffee maker a ‘game-changer’ in the home coffee machine category.

Oscar, CEO of Maxim’s Espresso said: “I’m delighted to be sharing our new baby with the world. Maxim’s has set a high watermark with its Michelin food, but we want to show the world that we take coffee seriously too.”

The Seine X’s patented MPF Multi-Frequency Stable Pressure Control™, allows the user to adjust the pressure of their espresso between a range of 3 to 15 bars. By tweaking the pressure, the user unlocks a myriad of complex flavors in every bean—ideal for experimenting with light roasts to dark blends.

A major selling point is the ‘super-steam’ wand, which can produce professional dry steam making effortless cappuccinos, flat whites and cortados. The integrated thermometer allows you to monitor the temperature of the milk in real time.

“Maxim’s machine is a game changer, it’s one of the most complete home espresso machines I’ve tested”, said Elida, a former judge for the World Barista Championships: “It’s possible the best espressos in the world can now be found at home.”

For those who appreciate the finer things—from an aged Bordeaux to hotels with a view—Maxim’s now invites you to elevate your morning with an espresso that rivals the quality of its cuisine.

Maxim’s has been synonymous with French elegance, culinary excellence, and the art of sophisticated living since 1893. Born as a Parisian restaurant on the iconic Rue Royale, we’ve been offering the world a taste of Parisian luxury for more than a century. For more information about Maxim’s Seine X, visit maximsespresso.com.

Media Contact

Eric Wilson
Maxim’s de Paris
hi@maximsespresso.com

Movemaker and alcove Launch US$200K Open-Source Initiative to Establish Secure Contract Library for Aptos Developers

Creating a Gold Standard for Truly Trustworthy, Reusable, and Auditable Infrastructure with the  Aptos Move Secure & General Purpose Base Library

HONG KONG, June 2, 2025 /PRNewswire/ — Movemaker, Aptos’ official Chinese-speaking community, and alcove, the first Asia-based Move developer organization, today announced the launch of the Aptos Move Secure & General Purpose Base Library, an open-source initiative to standardize and strengthen the Aptos smart contract ecosystem. The initiative comes in response to growing concerns over on-chain security and fragmented development practices in the Web3 space.

Backed by an initial US$200,000 in seed funding from Movemaker, the initiative will create a rigorously audited, reusable library of smart contract modules – covering critical areas such as access control, upgrade tools, DeFi primitives, and utility functions. The project aims to mirror the role of OpenZeppelin in the EVM ecosystem while leveraging the unique technical advantages of Move and Aptos, including resource-oriented programming, strong typing, and parallel execution.

“Despite Move’s inherent safety, we’ve seen developers repeatedly rebuild essential modules with varying quality and minimal audit coverage,” said Kaito, Core Contributor at Movemaker. “This project aims to eliminate duplication, improve security, and accelerate dApp development by providing a trusted foundation for all Aptos developers.”

The initiative is open to all Aptos builders and will be governed through transparent, community-led development on GitHub, incorporating automated testing, formal verification via Move Prover, peer reviews, and bounty incentives.

A full suite of tools and support will be provided for developers:

  • Core Module Library: Reusable components including access control, module upgrades, DeFi primitives, and security utilities.
  • Multi-language SDKs: Support for TypeScript, Python, Rust, Go, etc., to simplify on-chain operations.
  • Standardized APIs: Easier blockchain data access and interaction interfaces for app developers.
  • Developer Tooling Support: VS Code plugins, CLI extensions, debugging tools, and more for a better coding experience.
  • Templates and Example Projects: Ready-to-use boilerplates to help you build your own dApps quickly.

Developers can review details of the proposal and submit a PR here: https://github.com/ALCOVE-LAB/aptos-movekit

The Aptos Move Secure & General Purpose Base Library initiative welcomes contributions from project teams, independent developers, and security experts to collaborate together and help shape a robust, reusable foundation for the future of Move-based smart contract development.

About Movemaker

Movemaker is an official community organization authorized by the Aptos Foundation, jointly launched by Ankaa and BlockBooster, focused on developing and expanding the Aptos ecosystem within Chinese-speaking regions. As Aptos’ official representative in the region, Movemaker has received multi-million-dollar support and resources from the Aptos Foundation and is committed to building a diverse, open, and thriving ecosystem by connecting developers, users, capital, and partners.

From DeFi and AI to payments, stablecoins, and RWA, Movemaker supports the deployment of innovative applications and drives real-world connections for Aptos technology. As a key bridge for Aptos in Asia, Movemaker combines local narratives with global vision to inspire more developer participation in the ecosystem.

About alcove

alcove is the first Chinese-speaking Move developer community in Asia, co-built with the Aptos Foundation, focused on supporting developers in building the next generation of Web3 applications using Move. The community brings together a large number of developers experienced in Move low-level development, contract security, and tooling—and has contributed practical expertise to numerous Aptos projects.

CIMB Singapore and Wing Bank Forge Strategic Partnership to Boost Cross-Border Financial Services Between Singapore and Cambodia

SINGAPORE and PHNOM PENH, Cambodia, June 2, 2025 /PRNewswire/ — CIMB Singapore and Wing Bank (Cambodia) Plc have entered a strategic partnership through a Memorandum of Understanding (MoU) to enhance cross-border financial services and deepen economic collaboration between Singapore and Cambodia. 

This partnership represents a significant milestone in strengthening financial connectivity within ASEAN, leveraging CIMB Singapore’s regional expertise and Wing Bank’s local leadership to serve a broad spectrum of clients—from commercial enterprises and SMEs to high-net-worth individuals.

Clockwise, Dr. Dmytro Kolechko, CEO of Wing Bank, Neak Oknha KITH MENG, Chairman of the Board of Directors of Wing Bank and CEO of the Royal Group of Companies, and Victor Lee Meng Teck, CEO of CIMB Singapore and CEO of Growth Markets, are posing for a photo during the MoU signing ceremony.
Clockwise, Dr. Dmytro Kolechko, CEO of Wing Bank, Neak Oknha KITH MENG, Chairman of the Board of Directors of Wing Bank and CEO of the Royal Group of Companies, and Victor Lee Meng Teck, CEO of CIMB Singapore and CEO of Growth Markets, are posing for a photo during the MoU signing ceremony.

“Teaming up with CIMB Singapore allows us to bring world-class financial solutions to our customers while deepening Cambodia’s economic integration with Singapore,” said Dr. Dmytro Kolechko, CEO of Wing Bank. “This marks a pivotal step toward greater financial inclusion and cross-border opportunity.”

The alliance combines CIMB Singapore’s extensive regional expertise from its Singapore hub with Wing Bank’s deep-rooted presence in Cambodia, aiming to deliver seamless financial solutions for commercial banking clients, SMEs, and high-net-worth individuals. 

Victor Lee Meng Teck, CEO of CIMB Singapore and CEO of Growth Markets, added: “Our collaboration with Wing Bank reflects CIMB’s commitment to advancing financial inclusion and economic progress across ASEAN. Together, we will unlock new value for customers and strengthen the Singapore-Cambodia financial corridor.”

The collaboration will deliver seamless, tailored banking solutions, including deposits, loans, remittances, and trade finance to support growing demand from cross-border businesses. A key focus is to empower Cambodian SMEs, which form the backbone of Cambodia’s economy—accounting for 98% of businesses, 70% of employment, and 58% of GDP.

In 2024, Cambodia-Singapore trade surged to USD 103 million according to General Department of Customs and Excise of Cambodia–an impressive growth of 101% year-on-year, and a clear sign of intensifying economic synergy. This partnership will further streamline financial services, enabling smoother cross-border transactions and business growth. 

For high-net-worth individuals, the partnership will leverage CIMB Singapore’s hub—a leading ASEAN wealth management center—alongside Wing Bank’s local market expertise to offer sophisticated investment and wealth management solutions tailored to Cambodia’s evolving financial landscape. 

This landmark alliance sets the stage for a new era of Singapore-Cambodia financial integration, driving innovation, inclusion, and sustainable growth. By bridging two dynamic economies, CIMB Singapore and Wing Bank are paving the way for a more interconnected and prosperous ASEAN future.

For more information, please visit: https://www.wingbank.com.kh/en/category/company-news/

Health In Tech Chief Growth Officer to Be Featured on “New to The Street” Interview at NYSE

STUART, Fla., June 2, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is pleased to share that Chief Growth Officer Dustin Plantholt will be featured in an upcoming interview on “New to The Street,” filmed live at the New York Stock Exchange (NYSE) on June 3, 2025, at 10:00 AM ET.

Joining Mr. Plantholt for the interview are two key industry collaborators:

  • Chad A. Huff, Agency VP, Hilb Group
  • David Baily, Principal and Commercial Insurance Advisor, Baily Insurance

Together, they will explore how their collaboration is shaping smarter, more transparent health benefit solutions for small and mid-size businesses across the United States.

The full interview will broadcast on Bloomberg TV as part of sponsored business programming. In addition, a highlight segment from the interview will be featured on the Nasdaq MarketSite billboard in Times Square, bringing the story front and center to a global audience in one of the world’s most iconic locations.

“This interview marks an exciting milestone for Health In Tech and our valued partners,” said Dustin Plantholt. “Through our work with Hilb Group and Baily Insurance, we are helping to reshape the landscape of self-funded healthcare with solutions that are built on innovation, clarity, and trust.”

About Health In Tech

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

About Hilb Group

Hilb Group is a leading property and casualty and employee benefits insurance brokerage and advisory firm headquartered in Richmond, Virginia. Hilb Group is a portfolio company of The Carlyle Group, a global investment firm. Hilb Group seeks to grow through strategic acquisitions and by leveraging its resources and expertise to drive organic growth in its acquired agencies. The company has completed more than 190 acquisitions with over 125 offices in 31 states. Hilb Group is rated as one of the Fastest Growing Brokers by Business Insurance, a Top P/C Agency by Insurance Journal, and one of America’s Fastest Growing Private Companies in the Inc. 5000. For more information on Hilb Group’s growth as well as career opportunities, please visit our website at http://hilbgroup.com.

About Baily Insurance

Baily Insurance has been a trusted, faith-based, family-owned agency since 1880, providing tailored insurance solutions for individuals, families, and businesses. Learn more at http://bailyagency.com.

In pursuit of their mission to “Honor God with our work,” Baily Insurance also co-founded Fusion Health Plans, a national platform leveraging Health-In-Tech’s cutting-edge solutions. Fusion helps insurance brokers save their employer clients millions through smarter self-funded and level-funded benefit plans for groups of 25 to 250 employees. Explore more at http://www.fusionhealthplans.com.

Use of ForwardLooking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

Investor Contact

Investor Relations:
ir@healthintech.com

8 Incredible Places to Visit in and Around Chengdu—China’s City of Pandas, Hotpot, and Heritage

SHANGHAI, June 2, 2025 /PRNewswire/ — Once a hidden gem, Chengdu—the capital of China’s Sichuan province— is fast becoming one of the country’s most talked-about destinations. With an alluring blend of ancient tradition, fiery cuisine, and natural beauty (often showcased on social media), it’s no surprise that the city is a rising favourite, with pre-summer bookings up over 180%.

A notable rise in domestic and international flight routes, including greater connectivity via major hubs such as Shanghai and Beijing, is making the vibrant city more accessible than ever. 

And as travellers seek deeper, more immersive experiences beyond the bustling megacities, Chengdu, the City of Gastronomy designated by UNESCO, is emerging as the perfect counterpoint—rich in culture yet refreshingly laid-back.

For visitors looking to explore the city’s most iconic experiences, here are a few highlights that stand out:

1. Chengdu Research Base of Giant Panda Breeding

No visit to Chengdu is complete without meeting its most famous residents. The research base offers a rare opportunity to see giant pandas and red pandas in a carefully designed environment that mirrors their natural habitat. Enjoy an intimate experience with over 100 giant pandas and meet celebrity pandas Hua Hua and Qi Yi. The best viewing spots are Villas 1 and 2, where you can watch these majestic creatures play and snack on their favourite snack, bamboo. An unmissable experience is the panda cub enclosure, where you can observe 3-month-old cubs play, nap, and explore their surroundings. Make sure to visit in the morning when the pandas are most active and adorable. Find out more here: Chengdu Research Base of Giant Panda Breeding.

2. Margo Manor Hotpot

Spice is a way of life in Sichuan province, and nowhere is it more memorably served than at Margo Manor. This impressive hotpot restaurant blends stunning architecture, performance, and fiery Sichuan flavours into one unforgettable dining experience. It’s a must for lovers of bold cuisine, local flair and spicy flavours.

3. Taikoo Li Chengdu

Blending ancient Chinese architecture with modern luxury storefronts creates a cosmopolitan cool. This open-air shopping and lifestyle complex in the city’s heart is a case study in how Chengdu embraces the modern without losing its soul. Expect designer brands like Alexander McQueen, Gucci and Versace among cutting-edge galleries, and some of the city’s best cafés and cocktail bars, including %Arabica and Wang De Chuan Tea Company. Shoppers can also enjoy tax-free benefits at the nearby IFS (International Finance Square)—a convenient bonus for international travellers looking to indulge and conveniently process their tax refunds immediately after shopping at participating stores.

4. Chuancai Museum

Located in the northwest suburb of Chengdu, this interactive museum is the first of its kind in China. Visitors explore the history of Sichuan cooking with a sensory overload. Take in the smell of Sichuan’s famous peppercorn, an intoxicating, earthy perfume scent like no other. Or dive in and sample delicious Sichuan delicacies, including Sichuan-style stuffed pancake, northern Sichuan-style jelly, Tofu pudding, and dumplings. Not only will you observe the local gastronomic history, but you can also enjoy the museum through taste and smell, sampling famous local foods. Guests can even try their hand at preparing local dishes alongside expert chefs, who will take you on a culinary journey of Sichuan province. Find out more here: Sichuan Cuisine Museum.   

5. Chengdu Peoples Park

Chengdu Renmin Park is an essential stop for a taste of local life. This urban oasis allows visitors to experience the laid-back nature of the city from locals practising tai chi, families enjoying tea in open-air pavilions, and street musicians playing traditional instruments. Be sure to stop and sip on Chengdu’s famous jasmine tea, or even try the local tradition of ear-cleaning. A soothing experience that’s part cultural curiosity, part wellness ritual.

Side Trips Beyond the City

Thanks to Chengdu’s well-developed high-speed rail and domestic flight network, getting away from the city is easy and rewarding. Here are three must-see attractions, perfect for a day or weekend trip:

6. Jiuzhaigou Valley

On the edge of the Tibetan Plateau are the Min Mountains, which include the nature conservation site Jiuzhaigou Nature Reserve. A UNESCO World Heritage Site, famed for its crystal-clear lakes and lush wooded mountains. Jiuzhaigou is a nature lover’s dream. Spring sees the landscape in full bloom, making it a wonderful escape for hikers, photographers and anyone seeking peace in nature.

7. Mount Emei

Mount Emei, one of China’s Four Sacred Buddhist Mountains, offers spiritual tranquillity and dramatic mountain views. This UNESCO World Heritage Site is ideal for those up for a challenge; scaling its ancient stone stairways will ensure you’re standing on a sea of clouds, overlooking a breathtaking vista. Visitors can also take a leisurely stroll along its cliffside monasteries and potentially encounter the monkeys that inhabit the mountain.

8. Leshan Giant Buddha

Just a short train ride from Chengdu, this 71-metre-high stone Buddha statue, carved over a millennium ago, is the largest of its kind in the world. Viewed by boat or from a hillside path, it’s a staggering testament to ancient ingenuity and faith.

More about Chengdu: The International City of Intangible Cultural Heritage

Chengdu isn’t just a side trip—it’s becoming the main event with its unique pace of life and an abundance of experiences in and around the city!

The return of the biennial Chengdu International Intangible Cultural Heritage Festival (ICH) from 28 May to 3 June is adding to the city’s allure. The ICH Festival is a vibrant celebration of traditional arts, music and heritage, and further highlights the cultural pull of the vibrant Sichuan province and the uniqueness of Chengdu. This year’s festivities were organised in partnership with Trip.com Group. 

As part of the continued celebrations, Trip.Best Awards were also handed out: Trip.com’s AI-curated, expert-reviewed rankings, which spotlight the city’s must-see attractions, restaurants and hotels. For example, on the Trip.Best Chengdu list, local attractions include Wuhou Shrine, Sichuan Opera show and Chengdu Museum or find the best hotels in Chengdu.  

During the evening award show, guests were captivated by an eye-catching drone light show which stylishly told the history of China and Chengdu, while lively folk music and dances added to the atmosphere.

Chengdu is part of a growing wave of cities benefiting from China’s broader inbound tourism push. New visa-free policies, expanded rail connections, and digital-friendly travel tools make multi-city trips across China even more seamless. If you find yourself transiting in China, travellers can benefit from some amazing express tours – a free half-day layover tour designed to allow travellers to explore the charm and traditions of Shanghai or Beijing. Find out more on the Trip.com website: Beijing Express & Shanghai Express.

For more travel inspiration, check out the Trip.Best Asia 100 list or dive straight into Trip.Best Chengdu list and start planning your trip to China.

About  Trip.com

Trip.com is an international one-stop travel service provider, available in 24 languages across 39 countries and regions in 35 local currencies. Trip.com has an extensive hotel and flight network consisting of more than 1.5 million hotels and flights from over 640 airlines covering 3,400 airports in 220 countries and regions around the globe. Trip.com‘s world-class 24/7 multilingual customer service, as well as additional centres in Edinburgh, Tokyo and Seoul, help to ‘create the best travel experience’ for its millions of customers worldwide. To book your next trip, visit trip.com.

Taoping Selected for New US$2.8 Million Agricultural Product Supply Contract; Company Continues to Build Momentum in Important Growth Market

SHENZHEN, China, June 2, 2025 /PRNewswire/ — Taoping Inc. (Nasdaq: TAOP, the “Company”), a provider of innovative smart cloud platform services and solutions, today announced that it has been selected for a new RMB 20 million (US$2.8 million) sales and purchase agreement. Under the latest agreement with Hunan Xiuxiang Agricultural Technology Co., Ltd. (“Xiuxiang Agricultural”), the two parties will cooperate over a two-year period, during which Taoping will supply designated agricultural products.

Xiuxiang Agricultural, based in Changsha, Hunan Province, specializes in the sale of vegetable products. After studying Taoping’s state-of-the-art agricultural base in Mengla County, Yunnan Province, the company selected Taoping to help further modernize its operations and increase supply chain efficiency.

Today’s agreement follows the major agreement Taoping announced earlier this year for a project expected to generate an annual output value of RMB 600 million (US$83.3 million) by 2027 in Mengla County, Xishuangbanna Prefecture, Yunnan Province. The scope includes advanced agricultural planting, the efficient application of agricultural technologies, the incubation of high-tech enterprises, and agricultural ecological tourism.

Mr. Jianghuai Lin, Chairman and CEO of the Company, said: “I am very proud of our team for all of its hard work and continued execution. This is an exciting new growth market for us, where we can leverage our expertise to add tremendous value to our partners and, we believe, also unlock significant value for our shareholders. We are already seeing very high interest from potential partners, given the enormous demand for agricultural products, especially vegetables, in China due to its large population.”

“Our team has conducted several months of successful trials at our base in Mengla County, with positive improvements in both yield and quality of the products grown. We plan to further double down on our focus and investment in this large, new growth market, given the opportunities in front of us, including the newest contract we are announcing today. Moving forward, we will expand our planting areas, vigorously develop order-based agriculture, increase production capacity, and focus on market expansion. By providing high-quality agricultural products, we aim to meet customer demand and create additional revenue streams for the company.”

About Mengla County, Yunnan Province

Mengla County is located in the southeastern part of Yunnan Province, China, bordering Laos to the south. It is part of the Xishuangbanna Dai Autonomous Prefecture and is known for its tropical rainforest, rich biodiversity, and ethnic diversity, with significant Dai, Hani, and Yi populations. The county is home to parts of the Xishuangbanna National Nature Reserve, which protects endangered species like Asian elephants and gibbons. Mengla serves as an important trade hub between China and Laos, with the Mohan border crossing being a key point for cross-border commerce. The region’s economy is driven by tourism, agriculture (notably tea and rubber plantations), and trade.

About Taoping Inc.

Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping’s smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit http://en.taop.com.  You can also follow us on X.

Safe Harbor Statement

This press release contains “forward-looking statements” that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results, the effects of the global Covid-19 pandemic or other health crisis, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China’s legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting

CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity

CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs

Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant high-grade serous ovarian cancer (HGSOC) without CDH6 pre-selection

PRINCETON, N.J., June 2, 2025 /PRNewswire/ — OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced initial Ph1a data from its ongoing Phase 1 open-label, multicenter dose escalation and expansion study evaluating CUSP06, a CDH6-directed antibody-drug conjugate (ADC) with a differentiated profile, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. The data are being presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois.

“We are excited by the early results, especially in platinum-resistant HGSOC, which demonstrated promising activity in a heavily pretreated population without requiring CDH6 biomarker selection,” said Dr. Bing Yuan, Co-Founder and CEO of OnCusp Therapeutics. “These data, together with previously presented preclinical findings, underscore the best-in-class potential of CUSP06. We look forward to observing promising data in the Phase 1b study and to bringing this therapy to patients with ovarian cancer and other CDH6-expressing solid tumors.”

The Phase 1 trial is an open-label, multicenter, first-in-human study of CUSP06. The primary objective of the study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. The Phase 1a portion will determine the recommended doses for expansion and the Phase 1b portion will focus on further characterizing safety and efficacy in select tumor types.

As of May 13, 2025, data are available for 37 patients who have received CUSP06 once every three weeks (Q3W) at doses ranging from 1.6 to 5.6 mg/kg. These patients were heavily pretreated, with a median of 4 prior lines of therapy. Promising efficacy was observed in patients with heavily pretreated platinum-resistant HGSOC without CDH6 pre-selection. The overall response rate (ORR) was 36% in HGSOC (9/25; 5 confirmed (including 2 responders who had previously received mirvetuximab treatment) and 4 unconfirmed partial responses (PRs)). All patients with unconfirmed PRs remain on treatment. The ORR reached 50% at both 4.0 mg/kg + prophylactic granulocyte colony-stimulating factor (G-CSF) and 4.4 mg/kg + G-CSF cohorts (3/6 and 1/2 patients, respectively); all responders remain on treatment. The clinical benefit rate (CBR) was 92% (23/25). CA-125 responses occurred in 45% of Gynecologic Cancer InterGroup (GCIG)-evaluable HGSOC patients, further supporting clinical activity. Responses were seen in low and high-CDH6-expressing tumors. CUSP06 has been well tolerated, with manageable hematologic toxicities as the most common treatment-related adverse events. These Phase 1a safety and efficacy results support continued evaluation of CUSP06 in platinum-resistant HGSOC and other CDH6-positive tumors in Phase 1b expansion cohorts.

CUSP06 was recently granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with platinum-resistant ovarian cancer.

Poster Presentation Details:

Title: First-in-human (FIH) Phase 1 study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC), in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date and Time: June 21:30 PM CDT
Abstract Number: 3042
Poster Number: 357
Location: Hall A

About CUSP06

CUSP06, a CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a stable and homogeneous ADC. The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, this linker-payload has been shown to have an increased “bystander effect” compared with competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight. OnCusp obtained the exclusive global rights (outside of China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics in 2022. CUSP06 is being evaluated in a Phase 1 study in patients with platinum refractory/resistant ovarian cancer and other advanced solid tumors. Additional information on the CUSP06-1001 (NCT06234423) trial can be found at ClinicalTrials.gov.

About OnCusp Therapeutics

OnCusp Therapeutics, Inc., headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building biotech startups, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients. OnCusp raised an oversubscribed $100 million Series A financing round in January 2024, co-led by Novo Holdings, OrbiMed, and F-Prime Capital.

Contact:

OnCusp Investors & Media:

Argot Partners

OnCusp@argotpartners.com